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The 2015 emergence of Zika virus (ZIKV) in the Americas brought new attention to this previously obscure
virus. Experimental model systems have been instrumental in rapidly advancing our understanding of
ZIKV pathogenesis. Here, Lazear looks back on the events leading to the development of the ZIKV mouse
model reported in Cell Host & Microbe.My first interaction with Zika virus (ZIKV)
was as a handy addition to the virus
crossword emerging on the breakroom
whiteboard (down from the ‘‘z’’ in ‘‘influ-
enza’’ to the ‘‘a’’ from ‘‘Ebola’’). Always
fond of obscure viruses, I felt pretty
clever, though when asked what it was
I didn’t have much to say beyond ‘‘it’s a
flavivirus,’’ maybe adding ‘‘it’s causing
outbreaks in the Pacific’’ (Lazear and Dia-
mond, 2016). As a postdoctoral fellow in
Michael Diamond’s laboratory at Wash-
ington University in St. Louis, my research
focused on another flavivirus, West Nile
virus (WNV), particularly the roles of
different interferon subtypes in restricting
viral neuroinvasion and pathogenesis.
But after 5 years in the Diamond Labora-
tory, I was on the job market and looking
for open areas of research where I could
distinguish myself as a new investigator.
The emergence of new pathogens (and
re-emergence of old ones) is a constant
theme in arbovirus research, as travel
and commerce move infected humans,
animals, and arthropod vectors into new
areas. Examples in recent decades
include the introduction of WNV to North
America in 1999; independent introduc-
tions of chikungunya virus to Southern
Europe in 2007 and to the Western
Hemisphere in 2013; and the spread of
Schmallenberg virus across Europe since
2011. This is not a new phenomenon (the
trans-Atlantic slave trade brought yellow
fever virus to the Americas in the 17th cen-
tury) but modern travel has expedited it,
and climate change is likely to expand
the geographic areas affected. I wanted
to be prepared to study the next emerging
arbovirus, and I did not have to look far to
see evidence that this approach could
pay off: my own postdoctoral mentor
had started his laboratory at Wash U in2001, just as WNV was making its way
westward across the United States.
Although Mike had planned for his new
lab to work on dengue virus, the focus of
his postdoctoral training, he was able to
adapt this expertise to an emerging
flavivirus, quickly becoming a leader in
the field. More recently, what had
started as a minor research area in the
Diamond Laboratory, chikungunya virus,
had gained new relevance when this virus
was introduced to the Caribbean in 2013
(Diamond, 2015; Racaniello, 2016).
I thought the best candidate for the next
epidemic was Usutu virus, a flavivirus
similar to WNV. Though not yet a signifi-
cant cause of human disease, Usutu virus
had emerged in Eastern Europe over the
past decade and was making its way
westward, causing bird die-offs along
the way—reminiscent of WNV in North
America in the early 2000s. To get started,
I requested a sample of Usutu virus from
the World Reference Center for Emerging
Viruses and Arboviruses, at the University
of Texas Medical Branch (UTMB). While
I was at it, I also requested some other
potential emerging flaviviruses, including
Zika virus (ZIKV). This virus was even
more obscure than Usutu virus (almost
no experimental science published), but
it was causing outbreaks in the South
Pacific, so had potential to spread further.
Once the viruses arrived in the spring of
2015, I grew stocks and titrated them,
tested antibodies for cross-reactivity,
and infected mice. At the end of June,
Mike went to the National Institutes of
Health for a meeting on chikungunya virus
but found the coffee break conversations
dominated by ZIKV, as Brazilian re-
searchers described a growing outbreak
of febrile illness caused by this obscure
virus. Learning this, Mike returned toSt. Louis determined to apply his exper-
tise in flavivirus pathogenesis to this
emerging public health concern.
On Tues June 30, 2015, at 2:28PM
Diamond, Michael wrote:
Helen
Did we ever get the Zika virus
from UTMB?
Mike
On Tues June 30, 2015, at
3:34PM Lazear, Helen wrote:
Yep. I have it working in cell cul-
ture (virus stocks, FFA), and ASC
approval is pending (any up-
dates, Jen?)
There is an outbreak in Brazil
now. Importations much more
likely now than when it was just in
the South Pacific.
Helen
What had been a minor side project
(one I had not even bothered to mention
in job interviews) became more intense
that summer, as it became clear that the
ZIKV outbreak was spreading in Brazil.
Aside from the initial description of ZIKV
published in 1952, and one paper pub-
lished in 1971, there was no literature
describing ZIKV pathogenesis in animals
that we could use as a basis for our
studies—certainly nothing using modern
inbred mouse lines or transgenic animals.
Fortunately, we were able to draw on
our extensive experience studying other
flaviviruses in mice. Knowing that WNV
causes lethal disease in wild-type
(C57BL/6) mice but that dengue virus rep-
licates very poorly even in highly immuno-
deficient mice, I infected both wild-type
mice and ones with defective antiviral
responses. These included mice that
cannot respond to interferon (IFN-a/b)
(Ifnar1/), mice that lack transcription
factors required for IFN-a/b production
(Irf3/ 3 Irf5/ 3 Irf7/), and mice
with defective pattern recognition recep-
tor signaling (Mavs/), all of which suc-
cumb rapidly to WNV infection (Lazear
et al., 2013; Suthar et al., 2010). We even-
tually tested at least 18 different mouse
lines at different ages with a variety of
ZIKV strains, doses, and inoculation
routes. Among weaned mice (3 weeks
and older), we only observed morbidity
or mortality in lines that lacked an IFN-a/b
response (Ifnar1/, Ifnar1/3 Ifngr1/,
or Irf3/ 3 Irf5/ 3 Irf7/), consistent
with what other groups have since re-
ported (Aliota et al., 2016; Dowall et al.,
2016; Rossi et al., 2016; Yockey
et al., 2016).
While I focused on mouse experiments,
a post-baccalaureate student, Derek
Platt, and a graduate student, Estefania
Fernandez, worked to generate ZIKV re-
agents. We had not yet been able to
obtain any virus isolates from Brazil
(a challenge faced by many researchers
early in the ZIKV epidemic), but the Cen-
ters for Disease Control and Prevention
(CDC) had sent us a ZIKV isolate from
the South Pacific, thought to be the
source of ZIKV introduced to Brazil.
Mike and I had agreed that his group
would continue generating monoclonal
antibodies (a core expertise of the Dia-
mond Laboratory), while I would pursue
basic virology and pathogenesis ques-
tions as a side project in my new labora-
tory at the University of North Carolina at
Chapel Hill. At this point there was no indi-
cation that ZIKV was anything other than
the most recent in a series of old-world
arboviruses introduced to the Western
Hemisphere.
I was 3 weeks into my new position at
UNC when the news came of a surge
in microcephaly cases in northeastern
Brazil, the epicenter of the ZIKV epidemic.
On Wed Nov 18, 2015, at 9:58 AM,
Lazear, Helen wrote:
Mike -
What do you think about this
suggestion that ZIKV could be











I’m not aware of an associa-
tion with any other flaviviruses,
although theremay be associations
with some bunyaviruses (especially
in livestock). It seems that if it
happened with DENV at any
reasonable rate, we would know
about it. In utero infection with
WNV has been studied (by CDC)
and was associated with some
neurologic abnormalities, but spe-
cifically not microcephaly. I wonder
if drugs taken to treat symptoms
might be a more likely culprit?
It’s a huge increase in number
of cases.
Helen
On Wed Nov 18, 2015, at
11:49AM Diamond, Mike wrote:
Yes, I heard this from the Brazil-
ian colleagues
Not sure, but could be possible.
not seen with other flavis to my
knowledge
m
Early on, I was skeptical of a possible
association between ZIKV and micro-
cephaly, a congenital defect in which the
fetal brain fails to develop, because other
flaviviruses are not generally associated
with birth defects and ZIKV seemed only
to cause a self-limited febrile illness. How-
ever, a substantial body of evidence now
demonstrates that ZIKV infection during
pregnancy can result in Congenital Zika
Syndrome, a collection of developmental
disorders that includes microcephaly
(Coyne and Lazear, 2016).
Public interest in ZIKV surged in early
2016, with the spread of heartbreaking
images of Brazilian infants with tiny
misshapen heads. Realizing that ZIKV
was a much more significant human
pathogen than we had initially appreci-
ated, we felt a new sense of urgency to
publish our mouse infection data, since
small animal models are incredibly valu-
able for understanding mechanisms of
viral pathogenesis as well as evaluating
potential vaccines and therapeutics.
However, in my new laboratory I did not
yet have pipettes or a freezer, let alonethe large colony of knockout mice that 
would be necessary to complete this pa-
per. I am grateful to members of the Dia-
mond Laboratory, including Jonathan 
Miner, Amber Smith, and Jennifer Govero, 
who expended tremendous effort to com-
plete additional experiments in record 
time. They infected hundreds of immuno-
deficient mice with different ZIKV strains, 
watching and waiting to see whether any 
additional lines would succumb to infec-
tion. They detected high viral titers in tis-
sues such as the brain and testes that 
we now think are important for ZIKV path-
ogenesis. They also demonstrated that 
ZIKV can replicate in wild-type mice 
administered an IFNAR1-blocking mono-
clonal antibody, resulting in high viremia 
(though not lethality). Subsequent work 
in the Diamond laboratory by Jonathan, 
Jennifer, and others demonstrated that 
this increase in viremia is enough to elicit 
key ZIKV disease presentations including 
transplacental transmission, ophthalmo-
logical pathology, and damage to the 
testes with a concomitant decrease in 
male fertility (Govero et al., 2016; Miner 
et al., 2016a, 2016b). Although there are 
inherent limitations to studying viral path-
ogenesis in the absence of IFN-a/b 
signaling, having small animal models 
that replicate severe manifestations of 
ZIKV infection is important for developing 
interventions and for understanding the 
basic biology of ZIKV. Thanks to the effort 
and dedication of everyone involved, we 
were able to submit our paper to Cell 
Host and Microbe in March 2016 (Lazear 
et al., 2016). The urgency surrounding 
ZIKV research was reflected in the 
paper’s rapid turnaround: the revised 
version was accepted 10 days later. Un-
beknownst to us, Rossi and colleagues 
had already submitted a report of ZIKV 
infection in Ifnar1/ mice to the American 
Journal of Tropical Medicine and Hygiene 
(Rossi et al., 2016); when we first saw 
their publication (on the day ours was 
accepted), we knew this was the begin-
ning of a deluge of ZIKV publications.
When abstracts were due for the 2016 
American Society for Virology meeting, 
ours was the only one about ZIKV submit-
ted by the February 1 deadline. However, 
the field was moving so quickly that by 
May, two late-breaking workshops were 
added for the June meeting, including 
20 oral presentations and 9 posters. 
Among the many advances published in
Figure 1. The Author and Her 10-Day-Old
Son Attending the 2016 Meeting of the
American Society for Virology2016 were multiple ZIKV cryo-EM and
crystal structures; demonstrations of
ZIKV infection of and damage to neuronal
cells and organoids; studies in mice
modeling congenital and sexual transmis-
sion; investigations of antiviral immunity in
the placenta; and non-human primate
studies that replicated key features of
ZIKV disease in humans. While the field
moved from case reports to prospective
studies, a causal role for ZIKV in the
development of fetal microcephaly was
demonstrated, there was a growing
appreciation for the range of outcomes
that comprise Congenital Zika Syndrome,
evidence that ZIKV could be sexually
transmitted grew, and multiple ZIKV
vaccine candidates were developed and
began the early stages of clinical trials.
Although many questions remain about
the pathologic mechanisms of ZIKV, and
researchers will pursue these for years
to come, the pace of ZIKV research in
2016 truly was extraordinary. One factor
in the rapid progress of this research is
that ZIKV can be studied under biosafety
level 2 (BSL-2) containment (Centers for
Disease Control and Prevention, 2009).
This is an important difference between
ZIKV and other emerging viruses, such
as WNV, chikungunya, and MERS coro-
navirus, which must be handled under
BSL-3 containment, or Ebola and Nipah
viruses, which require BSL-4 contain-
ment. Policies that require higher levels
of biocontainment ‘‘out of an abundance
of caution’’ may underestimate the bene-
fits that come when diverse researchers
can easily study an emerging virus.
Although the CDC lists ZIKV as a BSL-2
agent, individual laboratories and institu-tions are free to require higher levels of
containment or additional safety precau-
tions; these range from none, to additional
signage, to supplementary personal pro-
tective equipment, to BSL-3 containment.
As we and other groups at UNC began
research with ZIKV, our institutional
biosafety committee (IBC) was chiefly
concerned with additional precautions to
protect pregnant women from ZIKV expo-
sure. Though surely a concern at other in-
stitutions as well, in January 2016 we
were in the unusual position of devising
policies to protect not just pregnant
women in general, but also one very spe-
cific pregnant woman, since I myself was
expecting my third child.
Early protocols submitted to our IBC by
other labs simply stated that pregnant
womenwould not workwith ZIKV, a policy
that would be unenforceable while also
creating a disincentive to disclosure. My
opinions about this were informed by my
experience as a postdoctoral fellow,
when I was pregnant with my first child.
When I told Mike that I was pregnant, he
asked that I stop doing BSL-3 sharps
work, due to the risk of a needlestick
exposure. Nearly all of my experiments
involved infectingmicewithWNV and har-
vesting their tissues, so it was no small
request when Mike asked another post-
doctoral fellow in the lab to do these ex-
periments for me. I was shocked and felt
that my project was being taken away,
and it was embarrassing to be burdening
someone else in the lab with my work.
Ironically, this postdoc was herself preg-
nant, though she had not yet revealed
this toMike or to the rest of the laboratory.
She continued to do her experiments and
mine, andmy experience discouraged her
from disclosing her pregnancy any earlier
than necessary. Two years later, when I
was pregnant with my second child, we
decided not to change any of my experi-
mental procedures. My experience left
me sensitive to the complex motivations
involved in these decisions, particularly
for a graduate student or postdoctoral
fellow with an intellectual and emotional
investment in a project. Now that I am a
Principal Investigator, I have come to
appreciate that the risks I might knowingly
take upon myself exceed those that I
would accept for my trainees. Carefully
considering the risks involved and
designing thoughtful policies to address
them is important to avoid penalizingwomen and to enable their informed deci-
sion making.
When considering the proper policies to
adopt for ZIKV research, our IBC’s ques-
tions ranged from the risks of a splash
exposure to whether I would be nimble
enough to catch an escaped mouse.
We ultimately agreed on a system of
enhanced information and consent for all
laboratory workers, additional warning
signs, and accommodations for women
who declined to work with ZIKV. We
decided that cell culture work was low-
risk under routine BSL-2 containment
and that the main exposure risk was nee-
dlesticks. Therefore, pregnant women
would be advised to avoid sharps
work with ZIKV. These precautions were
reasonable and enabled my new labora-
tory to begin work on most of our ZIKV
research projects but left me unable to
do the mouse infections that were my pri-
mary expertise; I owe many thanks to Ken
Plante, then a postdoctoral fellow in Mark
Heise’s laboratory, who stepped up to
infect mice with ZIKV while I could not.
The irony, given the measures we took
to find someone from another lab to assist
me with sharps work, was that I had spent
the earliest part of my pregnancy injecting
ZIKV into as many mice as possible (at
least 157 by my records), frantically trying
to generate data before leaving Wash U.
Of course, none of us had heard of
microcephaly then. As the evidence for
Congenital Zika Syndrome grew, along
with indications that the first trimester
may be an especially vulnerable time for
infection, I was thankful that I had no
reason to think that I had had an exposure
during those early experiments. My
healthy baby was born in June 2016 and
10 days later he was the youngest
attendee (I presume) at the American
Society for Virology meeting at Virginia
Tech (see Figure 1), where I convened
one of the late-breaking sessions on
ZIKV and presented our work developing
a mouse model of ZIKV pathogenesis.
I do not think you need to be pregnant, a
woman, or a parent to have your heart
ache for the children born from ZIKV-
affected pregnancies and the families
who care for them. However, I do think
that my experience has made me espe-
cially aware of the privilege I had to avoid
exposure to ZIKV while I was pregnant,
which sadly is not an option for many
women in ZIKV endemic areas. This
highlights the need for a vaccine to pre-
vent ZIKV infection, as well as better 
data about the factors that mediate trans-
placental transmission and the long-term 
prognosis for children exposed to ZIKV 
in utero, along with access to comprehen-
sive family planning services (including 
contraception and abortion) so that 
women confronted with ZIKV exposure 
can make informed decisions.
Despite the tremendous advances in 
our understanding of ZIKV during 2016, 
many questions remain about the basic 
virology and pathogenic mechanisms of 
this virus, as well as its epidemiology 
and clinical presentations. There are also 
technical hurdles to overcome for the 
development of serological diagnostics 
and an effective vaccine. The importance 
of these questions has attracted re-
searchers with diverse expertise; study-
ing Zika virus has provided an exciting 
opportunity to work with colleagues in 
neuroscience, developmental biology, 
and maternal-fetal medicine, as well 
as other virologists and immunologists. 
I have had the great fortune to be starting 
my new lab at UNC among incredibly sup-
portive neighbors and colleagues who 
have made it possible for my laboratory 
to move our ZIKV research forward, 
even before I was able to get all of our 
equipment and assays up and running. 
My laboratory has broad and ongoing in-
terests in ZIKV pathogenesis, including 
the impact of genetic changes betweenhistorical and contemporary ZIKV strains
on pathogenesis; the innate immune
mechanisms that control viral invasion
across anatomical barriers; and the
impact of host genetics and prior flavivi-
rus immunity on susceptibility to ZIKV dis-
ease. Mouse infection systems, and
particularly the model we reported in our
Cell Host & Microbe paper in 2016, are
proving to be key resources for address-
ing these and other questions in ZIKV
research.
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